US Pharma MarketingAngelini finds Catalyst for its US growth ambitions with $4.1B buyout
With an eye on the lucrative U.S. With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster Firdapse for $4.1 billion.
With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster Firdapse for $4.1 billion.
Source: FiercePharma